Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8037047 | 0.89 | SKP2 (0.40) | GPR84PTPN7DUSP3KDM4ETDP1 | |
| SCHEMBL16771200 | 0.84 | PNMT (0.55) | PNMTTAAR1KCNH2HPGDKMT2A | |
| SCHEMBL14426652 | 0.80 | KDM4E (0.42) | GPR84PTPN7DUSP3KDM4ETDP1 | |
| SCHEMBL91283 | 0.78 | GPR84 (0.44) | GPR84KDM4EPNMTTAAR1KCNH2 | |
| SCHEMBL12841593 | 0.78 | SKP2 (0.46) | PNMTTAAR1FFAR4KMT2ATP53 | |
| SCHEMBL20187505 | 0.78 | GPR84 (0.40) | GPR84PTPN7DUSP3KDM4EPNMT | |
| SCHEMBL23093144 | 0.77 | SKP2 (0.59) | KDM4ETDP1HPGDKMT2ATSHR | |
| SCHEMBL8914905 | 0.77 | ESR1 (0.59) | TDP1TAAR1TP53TSHR | |
| SCHEMBL662701 | 0.77 | TSHR (0.39) | PNMTTAAR1KCNH2HPGDKMT2A | |
| SCHEMBL13154800 | 0.77 | L3MBTL1 (0.38) | PNMTTAAR1KCNH2HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20100249163-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2010-09-30 | — | — | US | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
| WO-2009070869-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-06-11 | — | — | WO | disclosed |
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-04-02 | — | — | US | disclosed |
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-04-02 | — | — | US | disclosed |
| US-20090062342-A1 | AMINES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-03-05 | — | — | US | disclosed |
| US-20090062342-A1 | AMINES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-03-05 | — | — | US | disclosed |
| WO-2007102127-A2 | NEW AMINES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007099509-A2 | PRIMARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007088514-A1 | SECONDARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249163-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | GPR84 611/4885PTPN7 2576/4885DUSP3 1790/4885 |
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | REN, ACE, AGTR1 | GPR84 722/4885PTPN7 2752/4885DUSP3 3230/4885 |
| US-20090062342-A1 | AMINES | REN, ACE, MAOA | GPR84 1330/4885PTPN7 3843/4885DUSP3 3844/4885 |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | GPR84 1148/4885PTPN7 3471/4885DUSP3 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.